Clinical Trial Update: Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating every-3-week dosing of SCH 727965 in patients with advanced cancer (including Non-Hodgkin lymphoma and multiple myeloma) has been com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• SCH 727965

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Solid Tumors, Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED